Atypical antipsychotic use in a state hospital inpatient adolescent population.

Atypical antipsychotics are now the most commonly prescribed antipsychotics in young patients. These drugs are increasingly being used because of better tolerance and safety as seen in the adult populations. Youth with more severe psychopathology who are treated in the inpatient setting have been overlooked in much of the published research, and the extent of use and rationale in this population is unknown. This naturalistic retrospective study examined a population of adolescents in an inpatient state hospital setting with regard to their use of atypical antipsychotics. All patients who received an inpatient prescription for atypical antipsychotics between January 1, 1997 and June 1, 2000 and were ages 18 or younger at the time of medication initiation were included in the study. Twenty-three percent (88/380) of patients received an atypical antipsychotic: 68% (60/88) risperidone, 27% (24/88) olanzapine, and 5% (4/88) quetiapine. Psychotic disorders were considered as the primary diagnosis in only 17% of patients treated with atypical antipsychotics, and no particular diagnosis was predictive of monotherapy with an atypical antipsychotic. In the adolescent populations, atypical antipsychotics are being used for a wide variety of diagnoses and are commonly used adjunctively (more than 80%) with many concomitant psychotropic medications. More research is needed to develop useful and specific practice guidelines in children and adolescents for these commonly used medications.

[1]  A. Malhotra,et al.  Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. , 2006, Child and adolescent psychiatric clinics of North America.

[2]  E. Liebelt New drug therapies for diseases in children: from atypical antipsychotics to antivenom for snakebites. , 2005, Current opinion in pediatrics.

[3]  R. Weizman,et al.  Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[4]  R. Schweitzer,et al.  "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. , 2002, Schizophrenia bulletin.

[5]  C. Maffeis,et al.  Long-Term Effects of Childhood Obesity on Morbidity and Mortality , 2001, Hormone Research in Paediatrics.

[6]  S. Scott,et al.  Diabetic ketoacidosis associated with olanzapine in an adolescent patient. , 2001, The Journal of pediatrics.

[7]  S. Gupta,et al.  Risperidone-associated galactorrhea in a male teenager. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[8]  J. Buitelaar,et al.  A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. , 2001, The Journal of clinical psychiatry.

[9]  Duntas Lh Prolactinomas in children and adolescents--consequences in adult life. , 2001 .

[10]  S. Daniels Pharmacological Treatment of Obesity in Paediatric Patients , 2001, Paediatric drugs.

[11]  H. Parraga,et al.  Quetiapine treatment of children with Tourette's syndrome: report of two cases. , 2001, Journal of child and adolescent psychopharmacology.

[12]  S. Kutcher,et al.  Update and recommendations for the use of antipsychotics in early-onset psychoses. , 2001, Journal of child and adolescent psychopharmacology.

[13]  A. Cosenza,et al.  Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. , 2001, Journal of child and adolescent psychopharmacology.

[14]  M. Tohen,et al.  A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. , 2001, Journal of child and adolescent psychopharmacology.

[15]  J. Zislin,et al.  Risperidone in treating behavioural disturbances of Prader‐Willi syndrome , 2000, Acta psychiatrica Scandinavica.

[16]  J. Jureidini Epidemic of schizophrenia in children or inappropriate prescribing? , 2000, The Medical journal of Australia.

[17]  R. Findling,et al.  Paediatric uses of atypical antipsychotics , 2000, Expert opinion on pharmacotherapy.

[18]  M. Onofrj,et al.  Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide , 2000, Journal of Neurology.

[19]  S. Aysun,et al.  Weight gain associated with valproate in childhood. , 2000, Pediatric neurology.

[20]  L. Wilkinson,et al.  Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. , 2000, The Journal of clinical psychiatry.

[21]  M. Schluchter,et al.  A double-blind pilot study of risperidone in the treatment of conduct disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[22]  M. Salvatore,et al.  Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization , 2000, Clinical endocrinology.

[23]  K. Chang,et al.  Mood stabilizer augmentation with olanzapine in acutely manic children. , 2000, Journal of child and adolescent psychopharmacology.

[24]  J. Buitelaar Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. , 2000, Journal of child and adolescent psychopharmacology.

[25]  D. Cicchetti,et al.  Risperidone-associated weight gain in children and adolescents: a retrospective chart review. , 2000, Journal of child and adolescent psychopharmacology.

[26]  P. Muglia,et al.  Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. , 2000, Journal of child and adolescent psychopharmacology.

[27]  C. McDougle,et al.  Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. , 2000, Child and adolescent psychiatric clinics of North America.

[28]  G. Kewley Risperidone in comorbid ADHD and ODD/CD. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[29]  J. Biederman,et al.  Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  P. Keck,et al.  Olanzapine in the treatment of adolescent acute mania: a report of seven cases. , 1999, Journal of affective disorders.

[31]  L. Burke,et al.  Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[32]  W. Glazer,et al.  Neuroleptic-induced hyperprolactinemia , 1999, Schizophrenia Research.

[33]  C. McDougle,et al.  Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. , 1999, Journal of clinical psychopharmacology.

[34]  R. Malone,et al.  Novel antipsychotic medications in the treatment of children and adolescents. , 1999, Psychiatric services.

[35]  S. Stahl Peptides and psychiatry, Part 1: How synthesis of neuropeptides differs from classical neurotransmitter synthesis. , 1999, The Journal of clinical psychiatry.

[36]  J. Rapoport,et al.  Elevated prolactin in pediatric patients on typical and atypical antipsychotics. , 1999, Journal of child and adolescent psychopharmacology.

[37]  G. Hanna,et al.  Separation anxiety in children and adolescents treated with risperidone. , 1999, Journal of child and adolescent psychopharmacology.

[38]  J. Bregman,et al.  Open-label quetiapine in the treatment of children and adolescents with autistic disorder. , 1999, Journal of child and adolescent psychopharmacology.

[39]  J. Mccombs,et al.  Use patterns for antipsychotic medications in medicaid patients with schizophrenia. , 1999, The Journal of clinical psychiatry.

[40]  D. Rosenberg,et al.  Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. , 1999, Journal of child and adolescent psychopharmacology.

[41]  J. Rapoport,et al.  Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. , 1998 .

[42]  R. Conley,et al.  Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. , 1998, Journal of child and adolescent psychopharmacology.

[43]  H. Schreier Risperidone for young children with mood disorders and aggressive behavior. , 1998, Journal of child and adolescent psychopharmacology.

[44]  S. Fisman,et al.  Risperidone in PDD. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[45]  G. Bates,et al.  Movement disorder with fluoxetine. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[46]  C. McDougle,et al.  Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[47]  J. Gorman,et al.  Risperidone in adolescents with schizophrenia: an open pilot study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[48]  J. Busner,et al.  Prescribing practices of inpatient child psychiatrists under three auspices of care. , 1997, Journal of child and adolescent psychopharmacology.

[49]  C. Pataki,et al.  Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. , 1997, Journal of child and adolescent psychopharmacology.

[50]  D. Safer Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. , 1997, Journal of child and adolescent psychopharmacology.

[51]  J. Rapoport,et al.  Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison , 1996 .

[52]  Charles M Beasley,et al.  Olanzapine versus Placebo and Haloperidol , 1996, Neuropsychopharmacology.

[53]  S. Weiss,et al.  Lithium and Body Weight Gain , 1995, Pharmacopsychiatry.

[54]  B. Grannemann,et al.  Clozapine Treatment of Children and Adolescents with Bipolar Disorder and Schizophrenia: A Clinical Case Series , 1995 .

[55]  J. Rapoport,et al.  An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[56]  A. Roche,et al.  The predictive value of childhood body mass index values for overweight at age 35 y. , 1994, The American journal of clinical nutrition.

[57]  H. Remschmidt,et al.  An Open Trial of Clozapine in Thirty-Six Adolescents with Schizophrenia , 1994 .

[58]  Abraham Weizman,et al.  Clozapine treatment in very early onset schizophrenia. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[59]  W. Dietz,et al.  Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. , 1992, The New England journal of medicine.

[60]  H. Meltzer,et al.  Platelet imipramine binding in depressed children and adolescents. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[61]  S. Kapur,et al.  Clozapine for the treatment of adolescents with schizophrenia. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[62]  A Tremblay,et al.  Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. , 1990, Arteriosclerosis.

[63]  D Kromhout,et al.  Body Mass Index at the age of 18 and its effects on 32-year-mortality from coronary heart disease and cancer. A nested case-control study among the entire 1932 Dutch male birth cohort. , 1989, Journal of clinical epidemiology.

[64]  T. Van Itallie,et al.  Obesity: adverse effects on health and longevity. , 1979 .

[65]  G. Bray,et al.  Obesity: a serious symptom. , 1972, Annals of internal medicine.